E-ISSN: 1308-5263
Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study [Turk J Hematol]
Turk J Hematol. 2021; 38(4): 321-324 | DOI: 10.4274/tjh.galenos.2021.2021.0277  

Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study

Ahmet Omma1, Abdulsamet Erden1, Serdar Can Güven1, İhsan Ateş2, Orhan Küçükşahin3
1Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
2Ministry of Health Ankara City Hospital, Department of Internal Medicine, Ankara, Turkey
3Yıldırım Bayezıt University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey

Objective: The aim of this study is to investigate post-COVID-19 antibody titers in patients who received convalescent plasma (CP) in addition to standard-of-care treatment.
Materials and Methods: Hospitalized COVID-19 patients who received CP in addition to standard care were retrospectively investigated. Patients who received CP with a recorded total COVID-19 antibody test result after treatment were included. From among hospitalized COVID-19 patients who received only standard care with a recorded total COVID-19 antibody test result, a control group matched for age, gender, and comorbidities was formed. Total COVID-19 antibody index levels were compared.
Results: Thirty-three CP recipients were enrolled in the study. The control group consisted of 34 age-, gender-, and comorbiditymatched standard-care patients. Median total COVID-19 antibody index levels were significantly reduced in the CP group.
Conclusion: Although CP therapy may have benefits for disease outcome, its potential ability to hamper long-term immunity may be a problem.

Keywords: COVID-19, Convalescent plasma, Antibody, Immunity


Konvalesan Plazma COVID-19’da Endojen Antikor Yanıtını Azaltır: Retrospektif Kesitsel Bir Çalışma

Ahmet Omma1, Abdulsamet Erden1, Serdar Can Güven1, İhsan Ateş2, Orhan Küçükşahin3
1Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
2Ministry of Health Ankara City Hospital, Department of Internal Medicine, Ankara, Turkey
3Yıldırım Bayezıt University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey

Amaç: Çalışmanın amacı tedavi sürecinde standart tedavilere ek olarak konvalesan plazma (KP) tedavisi uygulanan COVID-19 hastalarında takipte oluşan COVID-19 antikor düzeylerini incelemektir.
Gereç ve Yöntemler: Yatarak tedavi alan COVID-19 hastaları içinde standart tedavilere ek olarak KP tedavisi alanlar retrospektif olarak incelenmiştir ve takipte COVID-19 antikor düzeyleri bakılmış olanlar çalışmaya dahil edilmiştir. Aynı zaman zarfında yatarak takip edilen, standart tedavi alan ve takipte COVID-19 antikor düzeyi bakılmış olan COVID-19 hastaları arasından yaş, cinsiyet ve komorbidite sıklığı eşleştirilmiş bir kontrol grubu oluşturulmuştur. İki grup arasında COVID-19 antikor düzeyleri karşılaştırılmıştır.
Bulgular: KP tedavisi alan ve takipte antikor düzeyleri bakılmış olan 33 COVID-19 hastası çalışmaya dahil edildi. Kontrol grubunda 34 hasta mevcuttu. Median total COVID-19 antikor indeks düzeyleri standart yaklaşıma ek olarak KP alan grupta anlamlı olarak düşük saptandı.
Sonuç: KP tedavisinin COVID-19 hastalarında sonuçlar üzerine olumlu etkileri görülmekle beraber hastalık sonrasında azalmış antikor yanıtı, uzun dönem bağışıklık üzerine olumsuz etkilerin bir göstergesi olabilir.

Anahtar Kelimeler: COVID-19, Konvelesan plazma, Antikor, Bağışıklık


Ahmet Omma, Abdulsamet Erden, Serdar Can Güven, İhsan Ateş, Orhan Küçükşahin. Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study. Turk J Hematol. 2021; 38(4): 321-324

Corresponding Author: Serdar Can Güven, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2020) = 1.831